News | Magnetic Resonance Imaging (MRI) | September 02, 2015

Swedish Hospital Installs SyMRI Neuro for Improved Follow-up of MS Patients

System allows automatic calculation of brain parenchymal fraction via MRI to quantify neurodegeneration

SyMRI, Linkoping University Hospital, MS, multiple sclerosis, brain parenchymal fraction

September 2, 2015 — Linköping University Hospital in Sweden has installed SyMRI Neuro from SyntheticMR in order to improve the follow-up of patients with multiple sclerosis (MS). SyMRI enables objective follow-up of brain atrophy through automatic calculation of brain parenchymal fraction (BPF). After an initial pilot project, the aim is to take SyMRI into clinical use in Region Östergötland during 2016.

Magnetic resonance imaging (MRI) is especially good at visualizing soft tissue in the body and is used in the investigation and monitoring of MS. With current methods, however, physicians are for the most part forced to make subjective judgments of the images, which can make it difficult to obtain a good and comparable measure of disease development.

“With SyMRI we can get an automatic measurement of brain atrophy, which means that we can now quantify the neurodegeneration that occurs in connection with MS. This allows for a better follow-up for our patients”, said Patrik Fägerstam, M.D., neuroradiologist at Linköping University Hospital.

SyMRI Neuro will be installed in the hospital’s picture archiving and communication system (PACS) from Sectra.

For more information:

Related Content

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform
Technology | Neuro Imaging | March 15, 2018
March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., ha
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
ContextVision Demonstrates VolarView and the Orthopedic Package at ECR 2018
Technology | Advanced Visualization | February 27, 2018
At this year’s European Congress of Radiology (ECR), Feb. 28-March 4 in Vienna, Austria, ContextVision will showcase...
Aidoc Introduces AI Solution for Whole-Body CT Scan Analysis
News | Artificial Intelligence | February 20, 2018
Deep learning startup company Aidoc announced what it calls the world’s first and only comprehensive, full-body...
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys...
Overlay Init